Vera Therapeutics

VERA

29.7851.18% ( -0.355 )

Closed: Nov 6, 16:00:00 (EDT)

Q3 FY2026 EarningsQ3 FY26 results significantly beat consensus as TRUTAKNA® (atacicept) commercial launch gained rapid momentum. Net product revenue reached $10.3M vs. $3.3M expected, driven by ~700 Patient Start Forms (PSFs) following July FDA approval. GAAP EPS of -$1.30 was notably narrower than the -$1.62 consensus, supported by a shift in manufacturing costs to inventory capitalization. Management's submission of an sBLA for full approval on November 3 and strong eGFR stabilization data provide a clear path to potential mid-2027 full approval.

Financial report interval: 2026.06.30 - 2026.09.30

Overview: Vera Therapeutics(VERA) the Revenue is 10.28 M (--%), Beat estimate;the EBIT is -95.7 M (-14.02%), Beat estimate;the EPS is -1.3 (-3.17%), Beat estimate.

Actual

YoY

Estimate

YoY

Vs estimate

YoY

RevenueExceed expectations

0.01B--

0.00B--

+0.01B--%

EBITExceed expectations

-0.10B14.02%

-0.12B42.65%

+0.02B28.63%

EPSExceed expectations

-1.33.17%

-1.6228.57%

+0.320025.40%

Upcoming earnings report - Annual FY2026

Available dateFeb 26, 2027

Estimate Revenue$23.12 M

Estimate EBIT-$465.14 M

Estimate EPS-$6.25

Revenue

ActualEstimateUnit: USD

Quarterly

EBIT

ActualEstimateUnit: USD

Quarterly

Net income

ActualEstimateUnit: USD

Quarterly

EPS

ActualEstimateUnit: USD

Quarterly